International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 1 | Views: 88 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Research Paper | Pharmacy | India | Volume 11 Issue 9, September 2022

Evaluation of Treatment Outcome for HIV Patients after TLD Regimen (Tenofovir, Lamivudine and Dolutegravir) using Viral Load Suppression

D. Vasuni Sai Mounika | K. Lokesh | Md. Salma Sulthana | A. Sudharshan Reddy

Abstract: Introduction: HIV is a virus that weakens the immune system of a person by destroying cells that fight against infection and disease. Dolutegravir-based regimens (TLD/ALD) were suggested by the WHO as the preferred first- and second-line antiretroviral therapy in 2018. Objective: To evaluate the treatment outcome of TLD regimen based on viral load suppression among HIV patients. Methods: A prospective observational study was conducted in government general hospital, Ongole for a period of six months. Efficacy of TLD regimen among 470 patients was assessed. Results: Our study involves 3,110 patients out of which 470 patients are included who are having age between 20-50 years old, undergoing TLD therapy, who are under follow up and whose medication adherence is documented. Of these patients, 321 individuals (68%) had virologic response to the TLD regimen, while virologic response was not achieved in 149 patients (32%). Conclusion: According to the results of our study, we conclude that the TLD regimen is 68% effective, andPatients in clinical stage 1, who had >95% adherence, were working, between the ages of 20 and 30, females showed better results in terms of viral suppression.

Keywords: HIV, Human immunodeficiency virus, TLD regimen, Tenofovir, Lamivudine and Dolutegravir, viral load, AIDS, Acquired immunodeficiency syndrome, Virologic suppression improvement

Edition: Volume 11 Issue 9, September 2022,

Pages: 232 - 234

How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link

Verification Code will appear in 2 Seconds ... Wait